Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses-Reference-Cited by-同舟云学术

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses

Published:2020-04-02 Issue:4 Volume:13 Page:331-349
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Musto Pellegrino¹,La Rocca Francesco²

Affiliation:

1. Chair of Hematology and Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico, “Aldo Moro” University, School of Medicine, Bari, Italy

2. Laboratory of Clinical Research and Advanced Diagnostics, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1740084

Reference113 articles.

1. Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma

2. Novel targets for the treatment of relapsing multiple myeloma

3. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action

4. CD38 as an immunotherapeutic target in multiple myeloma

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy;Drugs;2023-04

2. Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells;Cancers;2023-03-23

3. Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management;Cornea;2022-12-15

4. The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy;Journal of Cutaneous Pathology;2022-10-03

5. Antibody-drug Conjugate Targets, Drugs, and Linkers;Current Cancer Drug Targets;2022-07